Haig P. Bozigian Sells 26,250 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 26,250 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $1,575,000.00. Following the sale, the insider now directly owns 144,601 shares of the company’s stock, valued at approximately $8,676,060. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at 57.74 on Friday. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $60.00. The company’s market cap is $5.09 billion. The company’s 50 day moving average price is $52.69 and its 200-day moving average price is $48.43.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.01. The company had revenue of $6.34 million during the quarter, compared to the consensus estimate of $0.61 million. During the same period in the prior year, the firm posted ($0.46) EPS. On average, analysts forecast that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Haig P. Bozigian Sells 26,250 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/10/haig-p-bozigian-sells-26250-shares-of-neurocrine-biosciences-inc-nbix-stock.html.
A number of institutional investors and hedge funds have recently bought and sold shares of NBIX. The Manufacturers Life Insurance Company boosted its holdings in Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares during the period. First Mercantile Trust Co. boosted its holdings in Neurocrine Biosciences by 22.2% during the 1st quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock valued at $133,000 after acquiring an additional 560 shares during the period. ARS Investment Partners LLC purchased a new position in Neurocrine Biosciences during the 2nd quarter valued at $207,000. Stephens Inc. AR purchased a new position in Neurocrine Biosciences during the 2nd quarter valued at $207,000. Finally, Capstone Asset Management Co. purchased a new position in Neurocrine Biosciences during the 1st quarter valued at $214,000.
A number of analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday. ValuEngine raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Piper Jaffray Companies set a $68.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Thursday, August 24th. Cowen and Company reissued an “outperform” rating and set a $65.00 price objective (up previously from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. Finally, BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $68.25.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.